TScan Therapeutics, Inc. (TCRX) Form 8-K — Sep 30, 2026

$TCRXForm 8-KItems 5.02Filed Sep 30, 2026, 5:00 PM ET0001193125-26-409199Original filing

TScan Therapeutics entered into separation agreements with CFO Jason Amello (September 24, 2026) and CMO Dr. Chrystal Louis (September 25, 2026), formalizing their departures previously disclosed in a September 2 8-K as part of a strategic reorganization. Both executives' employment terminates on the earlier of November 1, 2026 or when they commence other employment. Each remains entitled to previously disclosed termination payments, plus milestone-based retention awards of $85,000 (Amello) and $125,000 (Louis) under the November 2025 retention program.

Key figures

Separation date: 2026-11-01
Louis retention award: 125000
Amello retention award: 85000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.